LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | SB590885 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 280 | 4513 | 0.0621 | -0.2916 |
| MDA-MB-231 | PIK-93 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 1916 | 4513 | 0.4246 | 0.2077 |
| MDA-MB-231 | KIN001-043 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1167 | 4513 | 0.2586 | -0.0209 |
| MDA-MB-231 | Alpelisib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 3575 | 4513 | 0.7922 | 0.7138 |
| MDA-MB-231 | Luminespib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 696 | 4513 | 0.1544 | -0.1645 |
| MDA-MB-231 | A443654 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 344 | 4513 | 0.0762 | -0.2721 |
| MDA-MB-231 | OSI-027 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1591 | 4513 | 0.3526 | 0.1085 |
| MDA-MB-231 | XMD11-85h | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1803 | 4513 | 0.3995 | 0.1730 |
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 234 | 4513 | 0.0518 | -0.3057 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 420 | 4513 | 0.0932 | -0.2487 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 552 | 4513 | 0.1224 | -0.2086 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 699 | 4513 | 0.1550 | -0.1636 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 3080 | 4513 | 0.6825 | 0.5628 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 506 | 4513 | 0.1123 | -0.2225 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 663 | 4513 | 0.1470 | -0.1747 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 1235 | 635 | 4513 | 0.1408 | -0.1831 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 1235 | 259 | 4513 | 0.0575 | -0.2980 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 454 | 4513 | 0.1007 | -0.2384 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 340 | 4513 | 0.0755 | -0.2732 |
| MDA-MB-231 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 3499 | 4513 | 0.7754 | 0.6906 |
| MDA-MB-231 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 4324 | 4513 | 0.9580 | 0.9421 |
| MDA-MB-231 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 2241 | 4513 | 0.4966 | 0.3068 |
| MDA-MB-231 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 939 | 4513 | 0.2080 | -0.0906 |
| MDA-MB-231 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 574 | 4513 | 0.1272 | -0.2019 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 638 | 4513 | 0.1415 | -0.1822 |